Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Provider
Therapeutics Advances in Medical Oncology
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
Breast Cancer Research
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Journal of Clinical Oncology
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01
Journal of Clinical Oncology
Nature Medicine
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Cancer Treatment Reviews
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Investigational New Drugs
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
Journal of Clinical Oncology
Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study
Nature
In situ tumour arrays reveal early environmental control of cancer immunity